KLP Kapitalforvaltning’s Corcept Therapeutics CORT Stock Holding History

KLP Kapitalforvaltning’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.57M	Buy	22,300 +600	+3%	+$64.5K	0.01%	643
2026 Q2	$1.89M	Buy	21,700 +900	+4%	+$54.3K	0.01%	808
2026 Q1	$838K	Buy	20,800 +600	+3%	+$22.4K	﹤0.01%	1130
2025 Q4	$703K	Hold	20,200	–	–	﹤0.01%	1232
2025 Q3	$1.68M	Buy	20,200 +800	+4%	+$57.9K	0.01%	760
2025 Q2	$1.42M	Sell	19,400 -6,200	-24%	-$450K	0.01%	805
2025 Q1	$2.92M	Sell	25,600 -1,000	-4%	-$60.9K	0.01%	563
2024 Q4	$1.34M	Buy	+26,600	New	+$1.39M	0.01%	842

Other funds holding CORT

Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

KLP Kapitalforvaltning's CORT Position: Q3 2026 in Review

KLP Kapitalforvaltning increased its Corcept Therapeutics (CORT) stake by 2.8% in Q3 2026, buying an estimated $64.5K and bringing the position to 22,300 shares worth $2.57M. The position accounts for 0.01% of the portfolio, ranked #643.

KLP Kapitalforvaltning first reported a position in CORT in Q4 2024 and has held it in 8 quarters since. The position peaked at $2.92M in Q1 2025. 280 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

KLP Kapitalforvaltning held 22,300 shares of Corcept Therapeutics worth $2.57M as of Q3 2026.
KLP Kapitalforvaltning bought 600 Corcept Therapeutics shares in Q3 2026, an estimated $64.5K.
Corcept Therapeutics made up 0.01% of KLP Kapitalforvaltning's portfolio in Q3 2026, its #643 holding.
KLP Kapitalforvaltning first reported a position in Corcept Therapeutics in Q4 2024 and has held it in 8 quarters since.
KLP Kapitalforvaltning's Corcept Therapeutics position peaked at $2.92M in Q1 2025.
280 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q3 2026, filed 10 Nov 2026.